181 related articles for article (PubMed ID: 2526108)
1. Differential neutralizing effect of tiopronin on the toxicity of neocarzinostatin and SMANCS: a new rescue cancer chemotherapy.
Oda T; Yamamoto H; Miki T; Maeda H
Jpn J Cancer Res; 1989 Apr; 80(4):394-9. PubMed ID: 2526108
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity of smancs in comparison with other anticancer agents against various cells in culture.
Oda T; Sato F; Yamamoto H; Akagi M; Maeda H
Anticancer Res; 1989; 9(2):261-5. PubMed ID: 2526613
[TBL] [Abstract][Full Text] [Related]
3. Facilitated internalization of neocarzinostatin and its lipophilic polymer conjugate, SMANCS, into cytosol in acidic pH.
Oda T; Sato F; Maeda H
J Natl Cancer Inst; 1987 Dec; 79(6):1205-11. PubMed ID: 2961908
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of SMANCS on rat mammary tumor induced by 7,12-dimethylbenz[a]anthracene.
Kimoto A; Konno T; Kawaguchi T; Miyauchi Y; Maeda H
Cancer Res; 1992 Feb; 52(4):1013-7. PubMed ID: 1531320
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of two-route chemotherapy using intraperitoneal neocarzinostatin and its antidote, intravenous tiopronin, for peritoneally disseminated tumors in mice.
Hasuda K; Kobayashi H; Kuroiwa T; Aoki K; Taniguchi S; Baba T
Jpn J Cancer Res; 1989 Mar; 80(3):283-9. PubMed ID: 2524462
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of non-specific resistance to tumors in the mouse using a poly(maleic-acid-styrene)-conjugated neocarzinostatin.
Suzuki F; Pollard RB; Maeda H
Cancer Immunol Immunother; 1989; 30(2):97-104. PubMed ID: 2480846
[TBL] [Abstract][Full Text] [Related]
7. [Tumor growth inhibitory effects of SMANCS, a poly (styrene-maleic acid) conjugated derivative of neocarzinostatin, on various tissue culture cells].
Suzuki F; Okuno Y; Maeda Y; Maeda H
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3305-12. PubMed ID: 2961306
[TBL] [Abstract][Full Text] [Related]
8. Role of natural killer cells and macrophages in the nonspecific resistance to tumors in mice stimulated with SMANCS, a polymer-conjugated derivative of neocarzinostatin.
Suzuki F; Pollard RB; Uchimura S; Munakata T; Maeda H
Cancer Res; 1990 Jul; 50(13):3897-904. PubMed ID: 2141295
[TBL] [Abstract][Full Text] [Related]
9. [Screening for antagonistic agents to the lethal toxicity of neocarzinostatin. II. Effects of various drugs in inhibiting the toxicity of neocarzinostatin in vivo].
Ouchi M; Toriyama K; Matsumoto T; Baba T
Jpn J Antibiot; 1988 Jan; 41(1):105-15. PubMed ID: 2966869
[TBL] [Abstract][Full Text] [Related]
10. Enhanced intestinal absorption of a hydrophobic polymer-conjugated protein drug, smancs, in an oily formulation.
Oka K; Miyamoto Y; Matsumura Y; Tanaka S; Oda T; Suzuki F; Maeda H
Pharm Res; 1990 Aug; 7(8):852-5. PubMed ID: 2146602
[TBL] [Abstract][Full Text] [Related]
11. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image.
Iwai K; Maeda H; Konno T
Cancer Res; 1984 May; 44(5):2115-21. PubMed ID: 6324996
[TBL] [Abstract][Full Text] [Related]
12. Binding to and internalization by cultured cells of neocarzinostatin and enhancement of its actions by conjugation with lipophilic styrene-maleic acid copolymer.
Oda T; Maeda H
Cancer Res; 1987 Jun; 47(12):3206-11. PubMed ID: 2953411
[TBL] [Abstract][Full Text] [Related]
13. [Stability of high molecular weight anticancer agent SMANCS and its transfer from oil-phase to water-phase. Comparative study with neocarzinostatin].
Hirayama S; Sato F; Oda T; Maeda H
Jpn J Antibiot; 1986 Mar; 39(3):815-22. PubMed ID: 3016359
[TBL] [Abstract][Full Text] [Related]
14. Reduction of hepatic metastases in rabbits by administration of an oily anticancer agent into the portal vein.
Yamasaki K; Konno T; Miyauchi Y; Maeda H
Cancer Res; 1987 Feb; 47(3):852-5. PubMed ID: 3026619
[TBL] [Abstract][Full Text] [Related]
15. Interferon induction by SMANCS: a polymer-conjugated derivative of neocarzinostatin.
Suzuki F; Munakata T; Maeda H
Anticancer Res; 1988; 8(1):97-103. PubMed ID: 2451896
[TBL] [Abstract][Full Text] [Related]
16. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy.
Maeda H
Adv Drug Deliv Rev; 2001 Mar; 46(1-3):169-85. PubMed ID: 11259839
[TBL] [Abstract][Full Text] [Related]
17. Combined effect of radiation and YM-881 (SMANCS) on murine tumors and bone marrow.
Ono K; Wandl E; Sasai K; Tsutsui K; Shibamoto Y; Takahashi M; Abe M
Acta Oncol; 1990; 29(4):455-9. PubMed ID: 2143908
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of orally administered SMANCS, a polymer-conjugated protein drug, in mice bearing various murine tumors.
Schmitt DA; Kisanuki K; Kimura S; Oka K; Pollard RB; Maeda H; Suzuki F
Anticancer Res; 1992; 12(6B):2219-24. PubMed ID: 1295469
[TBL] [Abstract][Full Text] [Related]
19. In vitro mode of action, pharmacokinetics, and organ specificity of poly (maleic acid-styrene)-conjugated neocarzinostatin, SMANCS.
Takeshita J; Maeda H; Kanamaru R
Gan; 1982 Apr; 73(2):278-84. PubMed ID: 6214446
[TBL] [Abstract][Full Text] [Related]
20. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Matsumura Y; Maeda H
Cancer Res; 1986 Dec; 46(12 Pt 1):6387-92. PubMed ID: 2946403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
